TOP > 外国特許検索 > BIOMARKER OF DEMENTIA WITH LEWY BODIES

BIOMARKER OF DEMENTIA WITH LEWY BODIES

外国特許コード F170008926
整理番号 (S2015-0752-N0)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP056828
国際公開番号 WO 2016143703
国際出願日 平成28年3月4日(2016.3.4)
国際公開日 平成28年9月15日(2016.9.15)
優先権データ
  • 特願2015-044353 (2015.3.6) JP
発明の名称 (英語) BIOMARKER OF DEMENTIA WITH LEWY BODIES
発明の概要(英語) Cholesterol, desmosterol and a ratio of the levels thereof are usable as a blood biomarker of Alzheimer's disease, frontotemporal lobar degeneration or dementia with Lewy bodies.
従来技術、競合技術の概要(英語) BACKGROUND ART
Biomarkers for diagnosis of disease progress and disease states that is useful for grasping, the selection of a patient, with the aid of a suitable selection of treatment, the discovery of new drugs and monitoring of side effects of essential for.
Lewy body dementia of the pathological feature is, in the cerebral cortex, amygdala and nucleus basalis of meynert central nervous system and the autonomic nervous system such as a large number of wide range in the appearance of Lewy bodies. Lewy body dementia is, the progressive cognitive impairment of the function, attention, significant variation of the level of wakefulness, delusions and hallucinations based on specific, idiopathic Parkinson's symptoms (the hand tremor, gait impairment and the like), REM sleep behavior disorder, irritable to the anti-psychotic, autonomous diarrhea, exhibit symptoms such as depression. In the Lewy body dementia, in a healthy elderly compared to the oxidation type α - in the cerebrospinal fluid is significantly increased helical Aβ1-40 and α - synuclein in a decrease in the blood has been reported (Non-Patent Document 1 and 2). In addition, in a healthy elderly compared to the (CoQ10) as well as coenzymes in serum Q10 in patients with Lewy body dementia but statistically significant decrease in, the ratio of cholesterol (CHO) CoQ10 (CoQ10/CHO) is not statistically significant difference, further, the age of onset between CoQ10 and CoQ10/CHO, and the MMSE (Mini Mental State Examination) score report that no correlation. In addition, the results of the experiment, CHO is touching is, at the discussion thereof, in a healthy elderly compared to CHO Lewy body dementia patient in a slight decrease the numerical value of the reference can be made according to the present embodiment, a statistically significant difference is not described in the (non-patent document 3).
Alzheimer's disease is, in recent years from an early failure of the slow onset and stored in a persistent cognitive decline and wherein the disease is a neurodegenerative disease. Amyloid of cerebrospinal fluid 1-42 and phosphorylated tau protein (A β), Alzheimer's disease is considered to be a useful biomarker (non-patent documents 4 and 5). In addition, the Alzheimer's disease, abnormal cholesterol metabolism occurs in the same manner as is believed to be. Alzheimer's disease patients compared to healthy elderly (DES) desmosterol level in the plasma does not change, desmosterol level is low in the cerebral spinal fluid have been reported (Non-Patent Document 6). On the other hand, in the plasma of Alzheimer's disease patients and illnesses desmosterol level lower than that of a healthy person is a report (Non-Patent Document 7 and Patent Document 1).
Is frontal lobe degeneration, frontal lobe and temporal lobe restricted to exhibit progressive degeneration is a disease, speech disorders and behavioral abnormalities clinically mainly characterized as non-Alzheimer's type dementia including modified. As a biomarker in the cerebral spinal fluid, tau protein, the TAR DNA binding protein of 43kD (TDP-43) have been identified (Non-Patent Document 8). Further, TDP-43 plasma phosphorylation phosphorylation of brain pathology and TDP-43 significant correlation with the severity scores, the severity of the likely to be useful as a biomarker has been indicated (non-patent documents 9 and 10). However, Lewy body dementia, frontotemporal lobe degeneration of the Alzheimer's disease or in distinguishing, the specificity of the biomarker has not been clarified.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • EISAI RANDD MANAGEMENT CO., LTD.
  • 発明者(英語)
  • IKEUCHI TAKESHI
  • KUWANO RYOZO
  • SATO YOSHIAKI
  • BERNIER FRANCOIS
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close